Clinical trials: Organoids, open to volunteers
Pancreatic Cancer, Adult, Cephalic Duodenopancreatectomy
Effects of Peptamen 1.6 in Malnourished Patients (or at Risk) With Pancreatic Neoplasia Undergoing Cephalic Pancreaticoduodenectomy (CPD): A Mechanistic Study
Malnutrition is a common challenge in patients with pancreatic cancer undergoing cephalic pancreaticoduodenectomy (CPD), impacting postoperative recovery and overall prognosis.
- Trial name
- NCT06852014
- Testing
- Dietary Supplement: Experimental Treatment with nutritional suplement A + nutritional suplement B, Dietary Supplement: Dietary Supplement: Experimental Treatment with nutritional suplement B + nutritional suplement A
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Unresectable Hepatocellular Carcinoma
A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Hepatocellular Carcinoma
This is a prospective, non-randomized, open-label, single-center phase II clinical trial. It aims to evaluate the efficacy and feasibility of using patient-derived tumor organoid drug sensitivity testing (DST) to guide…
- Trial name
- NCT07351513
- Testing
- Organoid Drug Sensitivity Testing-Guided Therapy
- Volunteers
- 94 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Ovarian Cancer Stage III, Ovarian Cancer Stage IV
Tumor Microenvironment in Ovarian Cancer
A detailed understanding of molecular mechanism of cancer genesis is fundamental to develop innovative and personalized therapies.
- Trial name
- MICO (NCT06272240)
- Testing
- Ovarian Cancer Organoids
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University of Udine
Rare Tumour
Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS
The objective of this Phase II, open-label, multicenter, non-randomised controlled clinical trial is to guide precision treatment for patients with rare tumours based on Patient-Derived Organoids/Next-Generation Sequencing drug…
- Trial name
- SPRING (NCT06692491)
- Testing
- Albumin-Bound Paclitaxel, Epirubicin, Gemcitabine
- Volunteers
- 200 people
- Sponsor
- Peking University Shenzhen Hospital
Myasthenia Gravis Generalized
PANORAMA: Neuromuscular Organoids for Refractory AChR+ Myasthenia Gravis
Myasthenia gravis (MG) is an autoimmune disease in which autoantibodies attack the neuromuscular junction, the site at which nerve cells communicate with muscle fibres, impairing signal transmission and causing fluctuating muscle…
- Trial name
- PANORAMA (NCT07717281)
- Where
- Italy
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Digestive System Diseases, Inflammatory Bowel Disease, Ulcerative Colitis Type
Intestinal Organoids
Over the last decade, the use of mini-organ or organoids has been increasingly developed in fundamental research. Indeed, digestive organoids represent an essential advance compared to classical culture systems (epithelial cell…
- Conditions
- Digestive System Diseases, Inflammatory Bowel Disease, Ulcerative Colitis Type, Crohn Disease
- Trial name
- BIOÏDES (NCT05294107)
- Testing
- additional biopsies
- Where
- France
- Volunteers
- 90 people
- Sponsor
- Rennes University Hospital
Locally Advanced Thyroid Gland Carcinoma, Thyroid Cancer
Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer
The current study aims to explore the potential advantages of chemotherapy that is implemented based on drug sensitivity testing.
- Trial name
- NCT06713057
- Testing
- Cyclophosphamide+Pemetrexed+5-Fluorouracil, Cyclophosphamide+Doxorubicin+5-Fluorouracil, Vindesine + Cisplatin
- Where
- China
- Volunteers
- 20 people
- Sponsor
- West China Hospital
Head and Neck Squamous Cell Carcinoma, Patient Derived Organoid
PDO Based Drug Sensitive Test in R/M HNSCC
To evaluate the consistency of drug efficacy between the clinical systemic treatment and drug sensitive test based on patient-derived organoid in R/M HNSCC patients, using a prospective and multicenter observational study to…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Patient Derived Organoid, Drug Sensitive Test in Vitro
- Trial name
- NCT06686342
- Testing
- No intervention, No Intervention: Observational Cohort
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Huashan Hospital
Circulating Tumor Cell, HNSCC
Using a 3D Culture Model for Circulating Tumor Cells Combined With Molecular Bioassays in Patients With HNSCC Cancer
Cancer has been a significant cause of human death in the recent two decades, although detection, diagnosis, and cancer treatments improved and evolved rapidly.
- Trial name
- NCT06755762
- Testing
- Organoid 3D culture
- Where
- Taiwan
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Breast Cancer
Developing Breast (Cancer) Organoids
Currently, only a few validated biomarkers and models exist guiding or predicting treatment response for specific patient groups.
- Trial name
- NCT05317221
- Testing
- Not an extra intervention, tissue taken in routine practice will be used.
- Where
- Netherlands
- Volunteers
- 60 people
- Sponsor
- Maastricht Radiation Oncology
Soft Tissue Sarcoma, Child
Organoid-based Sensitivity-guided Chemotherapy for Advanced / Refractory Pediatric Tumors
This is a prospective, open-label, single-arm, single-center study designed to evaluate the feasibility of using patient-derived organoid drug sensitivity analysis to guide chemotherapy for pediatric patients with refractory and…
- Trial name
- NCT07528079
- Testing
- treatment based on the results of drug sensitivity analysis
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Prostate Cancer, Prostate Cancer Metastatic Disease
Lab Research Using Mini-tumors to Study Prostate Cancer Treatments
For men with an aggressive form of prostate cancer, finding the right and effective treatment right away is challenging. Many of these men face a high risk of cancer recurrence: about half experience a relapse after surgery, and…
- Conditions
- Prostate Cancer, Prostate Cancer Metastatic Disease, Prostate Cancer Recurrent, Advanced Prostate Cancer
- Trial name
- PR3DICT (NCT07004582)
- Testing
- HDR brachytherapy, Diagnostic biopsy
- Where
- 3 sites in Netherlands
- Volunteers
- 600 people
- Sponsor
- Maastricht Radiation Oncology
Lung Cancer
Organoid-guided Personalized Treatment of Pleural Effusion
The study is a single-arm, single-center clinical research that utilizes patient-derived tumor organoids to predict drug sensitivity, thereby assisting clinicians in formulating treatment plans to benefit lung cancer patients…
- Trial name
- NCT06959173
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Henan Cancer Hospital
Ovarian Cancer
Patients Derived Organoids as a Promising Tool to Tailor Ovarian Cancer Therapies (PANDORA).
The association of clinical, pathogenesis and mutational profile of patients affected by ovarian cancer have improved the armamentarium of therapies available for medical doctors.
- Trial name
- PANDORA (NCT06229522)
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
Extensive-stage Small Cell Lung Cancer (ES-SCLC), Extensive-stage Small Cell Lung Cancer (SCLC)
Organoid-guided vs Topotecan Therapy in Relapsed Extensive-Stage Small Cell Lung Cancer
This study aims to provide personalized treatment options for patients with extensive-stage small cell lung cancer (SCLC) whose disease has worsened after initial chemotherapy.
- Conditions
- Extensive-stage Small Cell Lung Cancer (ES-SCLC), Extensive-stage Small Cell Lung Cancer (SCLC), Small Cell Lung Cancer ( SCLC )
- Trial name
- NCT07106528
- Testing
- Organoid Drug Sensitivity Testing-Guided Therapy, Topotecan
- Volunteers
- 128 people
- Sponsor
- Peking Union Medical College Hospital
Hepatocellular Carcinoma Resectable
Drug Sensitivity Testing-Based Tumor Organoids to Guide Adjuvant Therapy After Hepatectomy for Primary Liver Cancer
This is a single-center, prospective, non-randomized, open-label, phase II clinical trial aiming to evaluate the efficacy and feasibility of using patient-derived tumor organoid drug sensitivity testing (ODST) to guide…
- Trial name
- NCT07363356
- Testing
- Organoid Drug Sensitivity Testing-Guided Therapy
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Bipolar Disorder (BD), Organoids
Analysis of Early Neurodevelopmental Alterations in Bipolar Disorder Based on Cortical Organoid Models
Demonstrate the existence of neurodevelopmental alterations in organoids derived from samples of patients with bipolar disorder (BD) with a neurodevelopmental (ND) component, compared with patients with bipolar disorder (BD)…
- Conditions
- Bipolar Disorder (BD), Organoids, Neurodevelopmental Conditions
- Trial name
- BIPODEV (NCT06968598)
- Testing
- blood sample
- Volunteers
- 10 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Medulloblastoma
Targeting MYC in High-Risk Medulloblastoma
Medulloblastoma is the most common malignant brain tumor in children. Group 3 medulloblastoma (G3 MB) represents the most aggressive molecular subtype and is associated with poor prognosis, particularly in cases characterized by…
- Trial name
- MYCMB (NCT07694622)
- Testing
- Tumor tissue collection
- Where
- Italy
- Volunteers
- 35 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Metastatic Breast Cancer
Efficacy of Personalized Tumorogram-based Therapy in Cancer Established From Patient-derived Organoid (AVATAR)
A biopsy of a tumor lesion (breast or other localisation) will be performed for processing to establish avatars (patient-derived organoids -PDO).
- Trial name
- AVATAR (NCT06459791)
- Testing
- Biopsy
- Where
- 3 sites in France
- Volunteers
- 110 people
- Sponsor
- Institut Curie
Eye Abnormalities
Modeling Ocular Developmental Diseases From 3D Cultures of Optic Vesicle Organoids Derived From hiPSCs of Patients With Ocular Malformations
Ocular morphogenesis is a complex process starting as early as the 4th week of embryonic life, involving interactions between varioustissues of different origin and conserved genes.
- Trial name
- OrganoEye (NCT06408701)
- Testing
- Blood sampling
- Where
- 2 sites in France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Toulouse